Geode Capital Management LLC Has $2.21 Million Position in NeuroPace, Inc. (NASDAQ:NPCE)

Geode Capital Management LLC boosted its holdings in NeuroPace, Inc. (NASDAQ:NPCE) by 8.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 317,192 shares of the company’s stock after buying an additional 25,330 shares during the period. Geode Capital Management LLC owned approximately 1.09% of NeuroPace worth $2,211,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of NPCE. Millennium Management LLC boosted its holdings in NeuroPace by 13.3% in the 2nd quarter. Millennium Management LLC now owns 686,037 shares of the company’s stock valued at $5,186,000 after purchasing an additional 80,324 shares during the period. Bank of New York Mellon Corp acquired a new stake in NeuroPace during the second quarter worth about $257,000. Acadian Asset Management LLC increased its stake in NeuroPace by 46.0% during the second quarter. Acadian Asset Management LLC now owns 68,918 shares of the company’s stock valued at $520,000 after acquiring an additional 21,703 shares during the period. Barclays PLC raised its holdings in NeuroPace by 346.0% in the 3rd quarter. Barclays PLC now owns 20,633 shares of the company’s stock valued at $144,000 after acquiring an additional 16,007 shares in the last quarter. Finally, Rhumbline Advisers bought a new stake in shares of NeuroPace in the 2nd quarter worth approximately $111,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

NeuroPace Trading Up 4.1 %

Shares of NPCE stock opened at $12.42 on Wednesday. The company has a market capitalization of $370.71 million, a P/E ratio of -12.42 and a beta of 2.02. NeuroPace, Inc. has a 12-month low of $5.45 and a 12-month high of $18.15. The company has a quick ratio of 4.77, a current ratio of 5.59 and a debt-to-equity ratio of 6.03. The firm has a 50-day moving average price of $10.03 and a 200 day moving average price of $8.13.

NeuroPace (NASDAQ:NPCE) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.07. The firm had revenue of $21.06 million during the quarter, compared to analysts’ expectations of $19.33 million. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%. During the same period last year, the firm posted ($0.28) EPS. Research analysts forecast that NeuroPace, Inc. will post -1 earnings per share for the current fiscal year.

Analyst Ratings Changes

NPCE has been the topic of a number of recent research reports. Wells Fargo & Company decreased their price target on shares of NeuroPace from $15.00 to $13.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 13th. JPMorgan Chase & Co. lifted their price objective on NeuroPace from $9.00 to $14.00 and gave the company an “overweight” rating in a report on Tuesday, December 17th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $15.00.

Insider Buying and Selling

In other news, major shareholder Ltd. Kck sold 4,031 shares of the business’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $6.54, for a total transaction of $26,362.74. Following the completion of the sale, the insider now owns 5,521,874 shares in the company, valued at $36,113,055.96. The trade was a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold a total of 246,239 shares of company stock worth $1,363,038 in the last 90 days. Corporate insiders own 22.20% of the company’s stock.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.